Login / Signup

Beta-amyloid interacts with and activates the long-form phosphodiesterase PDE4D5 in neuronal cells to reduce cAMP availability.

Yuan Yan SinRyan T CameronMelissa SchepersRuth MacLeodTom A WrightDean PaesDaniel van den HoveEmily WillemsTim VanmierloJos PrickaertsConnor M BlairGeorge S Baillie
Published in: FEBS letters (2024)
Inhibition of the cyclic-AMP degrading enzyme phosphodiesterase type 4 (PDE4) in the brains of animal models is protective in Alzheimer's disease (AD). We show for the first time that enzymes from the subfamily PDE4D not only colocalize with beta-amyloid (Aβ) plaques in a mouse model of AD but that Aβ directly associates with the catalytic machinery of the enzyme. Peptide mapping suggests that PDE4D is the preferential PDE4 subfamily for Aβ as it possesses a unique binding site. Intriguingly, exogenous addition of Aβ to cells overexpressing the PDE4D5 longform caused PDE4 activation and a decrease in cAMP. We suggest a novel mechanism where PDE4 longforms can be activated by Aβ, resulting in the attenuation of cAMP signalling to promote loss of cognitive function in AD.
Keyphrases
  • induced apoptosis
  • mouse model
  • cell cycle arrest
  • protein kinase
  • signaling pathway
  • endoplasmic reticulum stress
  • cognitive decline
  • oxidative stress
  • cell proliferation
  • pi k akt
  • crystal structure